Annual results and Q4 2024
Friday, January 31, 2025
Media release: English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)
Condensed financial report (PDF 0.5 MB)
Quarterly impact and sustainability update (ESG):
Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)
Download the presentation (PDF 4.7 MB)
Download the podcast (MP3 30 MB)
| Key figures1 | Continuing operations2 | ||
|---|---|---|---|
| Q4 2024 (USD m) | Q4 2023 (USD m) | % change (USD/cc) | |
| Net sales | 13,153 | 11,423 | 15 (cc: 16) |
| Operating income | 3,530 | 2,582 | 37 (cc: 39) |
| Net income | 2,820 | 2,638 | 7 (cc: 6) |
| EPS (USD) | 1.42 | 1.29 | 10 (cc: 10) |
| Free cash flow | 3,635 | 2,141 | 70 |
Core | |||
| Operating income | 4,859 | 3,821 | 27 (cc: 29) |
| Net income | 3,933 | 3,126 | 26 (cc: 29) |
| EPS (USD) | 1.98 | 1.53 | 29 (cc: 33) |
- Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
- As defined on page 35 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing corporate activities, and Discontinued operations include operational results from the Sandoz business.